Oura vs Whoop: pricing health wearables after the IPO was postponed
Oura postponed its IPO on 29 September, eight days after setting a range that valued it at $13.5B on basic shares at the midpoint. That leaves private rounds as the prices for the category: Oura at $10.9B, Whoop at $10.1B, and Eight Sleep next at $1.5B. Here is how Oura and Whoop compare on scale, funding and valuation.
By Boris Bavinck and Dealroom Next-Gen API · · Updated Similar valuations, with more funding recorded for Oura
Funding and employee data: September 2026
Source: Dealroom.co
Oura's latest private valuation is $10.9B, from September 2025; Whoop reached $10.1B in March 2026. Their recorded employee counts are also close. Oura has raised $1.25B in disclosed venture rounds, compared with $980M for Whoop. These totals exclude debt and secondary transactions, and omit undisclosed amounts.
Whoop reached $1B first; Oura reached $10B first
Private-round valuations and postponed IPO range midpoint · $B USD
Starts January 2020 at the last recorded valuations. Lines connect rounds; early values are Dealroom estimates. Dashed: midpoint of Oura’s postponed IPO range on basic shares; Whoop’s last round carried forward.
Source: Dealroom.co · Oura S-1/A
Whoop passed $1B in October 2020, ahead of Oura in April 2022. Oura then reached $10.9B in September 2025; Whoop followed six months later. The gap between their latest private valuations is small beside the gap to the next company, Eight Sleep at $1.5B.
Oura's filing set a range of $40–44 per share: $12.8B–$14.1B on basic shares, with a $13.5B midpoint. On 29 September, eight days after launching the offering, Oura postponed the IPO, citing uncertainty in the IPO market. It has not withdrawn the filing. Until it lists, the private rounds on this page remain the reference prices for Oura, Whoop and their peers.
Their commercial disclosures measure different things
Revenue and bookings run-rate are not comparable. Member counts also differ in date and definition.
Source: Oura S-1/A · WHOOP company announcement
Oura's accounts allow a revenue comparison over time. Whoop's release gives a bookings run-rate, which cannot establish its revenue relative to Oura. A shared revenue chart or valuation-to-revenue ranking would therefore overstate what the disclosures support.
Oura led wearable funding in 2025; Whoop leads in 2026
Selected health-wearables cohort · 2026 to 29 September
Source: Dealroom.co
Oura's $900M Series E accounted for 76% of the selected cohort's venture funding in 2025. Whoop's $575M Series G accounts for 68% in 2026 to date. The remaining companies raised $281M and $272M respectively; the latest year is incomplete.
Dexcom backs Oura and Abbott backs Whoop. These relationships connect the two wearables companies with glucose-monitoring businesses. Oura also has Eli Lilly as an investor; Whoop has Mayo Clinic. The financing records establish investment relationships, not the commercial results of those partnerships.
Eight Sleep is the nearest private peer at $1.5B
Selected private peers · latest valuations since 2022, at least $50M
US
US*Oura extension: midpoint of the postponed IPO range, on basic shares. Other bars retain their private-round dates.
Source: Dealroom.co · Oura S-1/A
Below Oura and Whoop, Eight Sleep is the only company in this selection above $1B. Biolinq follows at a $400M Dealroom estimate, then Ultrahuman at $363M. These observations come from different funding rounds and dates; they are not current market prices.
Sources and methodology
Dealroom company profiles, private valuations, round participants and funding amounts use a next-gen API snapshot dated 29 September 2026. This article is generated from that saved snapshot and does not refresh on each visit. The build cross-checks displayed API figures against the retained source observations.
Oura's IPO range, share count and financial figures come from its 21 September 2026 S-1/A. The postponement on 29 September 2026 is taken from TechCrunch's report of that day. Trailing revenue is calculated as fiscal 2025 plus the nine months to June 2026 minus the corresponding prior-year period. WHOOP's 31 March 2026 release supplies its bookings run-rate and membership disclosure. Missing comparable figures are left unfilled.
The funding chart follows 35 selected consumer-health wearable companies across rings, bands, sleep hardware and consumer glucose monitoring. It includes Sky Labs' historical financing; Sky Labs is excluded from the private ranking following its listing. One duplicate profile is excluded. Annual sums use rounds marked as venture in Dealroom; undisclosed amounts are omitted. The classification follows the API, so a round containing multiple financing components may require further separation. This is a selected cohort, not the entire wearable market.
The ranking shows selected private companies with valuation observations from 2022 onwards of at least $50M. Supersapiens is excluded because the research flagged its operating status as uncertain. Earlier observations are excluded, and estimated values are labelled. Oura's September 2025 API valuation is $10.9B, versus $11B as announced. For Eight Sleep the March 2026 observation is used, not the disputed August 2025 value. Oura's early valuations through 2021 and Whoop's through 2019 are estimates.
What the comparison shows
Oura and Whoop are close on private valuation and recorded headcount, and both attract large financing rounds. Their published commercial figures do not yet allow a like-for-like revenue comparison. With Oura's IPO postponed, neither company has a public price. Their last private rounds, $10.9B and $10.1B, remain the reference for each other and for the smaller private peers.